CAS 1439934-41-4

CTX-0294885

Description:

CTX-0294885, identified by its CAS number 1439934-41-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of cancer treatment. As a small molecule, it is designed to interact with specific biological targets, potentially inhibiting pathways that contribute to tumor growth and proliferation. The compound's structure typically includes functional groups that enhance its solubility and bioavailability, making it suitable for therapeutic applications. Its mechanism of action may involve modulation of signaling pathways or direct interaction with proteins involved in cancer cell survival. Preclinical studies often assess its efficacy, safety profile, and pharmacokinetics, which are crucial for determining its potential as a viable treatment option. As with many investigational drugs, ongoing research is essential to fully elucidate its characteristics, including its pharmacodynamics, potential side effects, and optimal dosing regimens. Overall, CTX-0294885 represents a promising avenue in the development of targeted cancer therapies.

Benzamide, 2-[[5-chloro-2-[[4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-

CAS: 1439934-41-4

Formula: C₂₂H₂₄ClN₇O

Purity: 98%

Color and Shape: Solid

Molecular weight: 437.9253

Ref: IN-DA001IPI

2-((5-Chloro-2-((4-(Piperazin-1-Yl)Phenyl)Amino)Pyrimidin-4-Yl)Amino)-N-Methylbenzamide

CAS: 1439934-41-4

2-((5-Chloro-2-((4-(Piperazin-1-Yl)Phenyl)Amino)Pyrimidin-4-Yl)Amino)-N-Methylbenzamide

Purity: 98%

Molecular weight: 437.93g/mol

Ref: 54-OR1023234

CTX-0294885

CAS: 1439934-41-4

CTX-0294885

Purity: ≥95%

Molecular weight: 437.93g/mol

Ref: 54-BUP12110

CTX-0294885

CAS: 1439934-41-4

CTX-0294885, a bisanilino pyrimidine, inhibits many kinases; used for Sepharose-based kinase capture.

Formula: C₂₂H₂₄ClN₇O

Purity: 98.73% - ≥95%

Color and Shape: Solid

Molecular weight: 437.93

Ref: TM-T2042

CTX-0294885

CAS: 1439934-41-4

CTX-0294885 is a synthetic, selective inhibitor of the tyrosine kinase receptor aurora A. It has been shown to have synergistic effects in vitro with the drug piperidine, which inhibits histone deacetylase and alters cellular signaling pathways. CTX-0294885 has been shown to inhibit cell growth in various cancer models and was effective at inhibiting tumor metastasis. CTX-0294885 was also found to have a higher potency than other inhibitors of aurora A, but not as potent as drugs that inhibit aurora B. This drug may be used as a therapeutic strategy for cancer treatment.

Formula: C₂₂H₂₄ClN₇O

Purity: Min. 95%

Molecular weight: 437.93 g/mol

Ref: 3D-PHC93441